Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: influenza virus vaccines - Vivaldi Biosciences

Drug Profile

Research programme: influenza virus vaccines - Vivaldi Biosciences

Alternative Names: A/H7N9 LAIV - Vivaldi Biosciences; delta-NS1 LAIV for paediatrics - Vivaldi Biosciences; Influenza A/H7N9 vaccine - Vivaldi Biosciences; Int-NS1 LAIV - Vivaldi Biosciences; VB-126

Latest Information Update: 28 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vivaldi Biosciences
  • Developer National Institute of Allergy and Infectious Diseases; Vivaldi Biosciences
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H7N9 subtype; Influenza virus infections

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for preclinical development in Influenza-A virus H7N9 subtype(Prevention) in USA (Intranasal)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections(In the elderly, Prevention) in USA (Intranasal)
  • 21 Jan 2014 Preclinical development is ongoing for seasonal Influenza virus infections (prevention, in the elderly) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top